Frontiers in Aging Neuroscience (Nov 2021)
18F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies
- Michinori Ezura,
- Akio Kikuchi,
- Akio Kikuchi,
- Nobuyuki Okamura,
- Nobuyuki Okamura,
- Aiko Ishiki,
- Aiko Ishiki,
- Takafumi Hasegawa,
- Ryuichi Harada,
- Shoichi Watanuki,
- Yoshihito Funaki,
- Kotaro Hiraoka,
- Toru Baba,
- Naoto Sugeno,
- Shun Yoshida,
- Junpei Kobayashi,
- Michiko Kobayashi,
- Ohito Tano,
- Shun Ishiyama,
- Takaaki Nakamura,
- Ichiro Nakashima,
- Ichiro Nakashima,
- Shunji Mugikura,
- Ren Iwata,
- Yasuyuki Taki,
- Katsutoshi Furukawa,
- Katsutoshi Furukawa,
- Hiroyuki Arai,
- Shozo Furumoto,
- Manabu Tashiro,
- Kazuhiko Yanai,
- Yukitsuka Kudo,
- Atsushi Takeda,
- Masashi Aoki
Affiliations
- Michinori Ezura
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
- Akio Kikuchi
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
- Akio Kikuchi
- Department of Occupational Therapy, Yamagata Prefectural University of Health Sciences, Yamagata, Japan
- Nobuyuki Okamura
- Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan
- Nobuyuki Okamura
- Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan
- Aiko Ishiki
- Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
- Aiko Ishiki
- Division of Community of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan
- Takafumi Hasegawa
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
- Ryuichi Harada
- Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan
- Shoichi Watanuki
- Division of Cyclotron Nuclear Medicine, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
- Yoshihito Funaki
- Division of Radiopharmaceutical Chemistry, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
- Kotaro Hiraoka
- Division of Cyclotron Nuclear Medicine, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
- Toru Baba
- Department of Neurology, National Hospital Organization Sendai Nishitaga Hospital, Sendai, Japan
- Naoto Sugeno
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
- Shun Yoshida
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
- Junpei Kobayashi
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
- Michiko Kobayashi
- 0Division of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan
- Ohito Tano
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
- Shun Ishiyama
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
- Takaaki Nakamura
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
- Ichiro Nakashima
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
- Ichiro Nakashima
- 0Division of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan
- Shunji Mugikura
- 1Department of Diagnostic Radiology, Tohoku University Graduate School of Medicine, Sendai, Japan
- Ren Iwata
- Division of Radiopharmaceutical Chemistry, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
- Yasuyuki Taki
- 2Department of Nuclear Medicine and Radiology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
- Katsutoshi Furukawa
- Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
- Katsutoshi Furukawa
- Division of Community of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan
- Hiroyuki Arai
- Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
- Shozo Furumoto
- Division of Radiopharmaceutical Chemistry, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
- Manabu Tashiro
- Division of Cyclotron Nuclear Medicine, Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
- Kazuhiko Yanai
- Department of Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Japan
- Yukitsuka Kudo
- Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
- Atsushi Takeda
- Department of Neurology, National Hospital Organization Sendai Nishitaga Hospital, Sendai, Japan
- Masashi Aoki
- Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan
- DOI
- https://doi.org/10.3389/fnagi.2021.761010
- Journal volume & issue
-
Vol. 13
Abstract
Introduction: We aimed to determine whether in vivo tau deposits and monoamine oxidase B (MAO-B) detection using 18F-THK5351 positron emission tomography (PET) can assist in the differential distribution in patients with corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Alzheimer’s disease (AD) and whether 18F-THK5351 retention of lesion sites in CBS and PSP can correlate with clinical parameters.Methods:18F-THK5351 PET was performed in 35 participants, including 7, 9, and 10 patients with CBS, PSP, and AD, respectively, and 9 age-matched normal controls. In CBS and PSP, cognitive and motor functions were assessed using the Montreal Cognitive Assessment, Addenbrooke’s Cognitive Examination–Revised, and Frontal Assessment Battery, Unified Parkinson’s Disease Rating Scale Motor Score, and PSP Rating Scale.Results:18F-THK5351 retention was observed in sites susceptible to disease-related pathologies in CBS, PSP, and AD. 18F-THK5351 uptake in the precentral gyrus clearly differentiated patients with CBS from those with PSP and AD. Furthermore, 18F-THK5351 uptake in the inferior temporal gyrus clearly differentiated patients with AD from those with CBS and PSP. Regional 18F-THK5351 retention was associated with the cognitive function in CBS and PSP.Conclusion: Measurement of the tau deposits and MAO-B density in the brain using 18F-THK5351 may be helpful for the differential diagnosis of tauopathies and for understanding disease stages.
Keywords
- tau deposits
- 18F-THK5351
- positron emission tomography (PET)
- corticobasal syndrome (CBS)
- Alzheimer’s disease (AD)
- tauopathy
